OraSure Reports Fourth Quarter 2024 Financial Results

Rhea-AI Summary

OraSure Technologies (NASDAQ: OSUR) reported Q4 2024 financial results showing total net revenues decreased 51% to $37.4 million from $75.9 million in Q4 2023, primarily due to declining COVID-19 revenues. Core revenues increased 10% year-over-year to $36.5 million, with Diagnostics revenues up 9% to $18.8 million and Sample Management Solutions up 14% to $14.8 million.

The company reported a GAAP operating loss of $12.4 million compared to operating income of $3.9 million in Q4 2023. Cash and cash equivalents stood at $267.8 million. Notable developments include the acquisition of Sherlock Biosciences to expand molecular diagnostics capabilities, FDA approval for expanded age range of OraQuick HIV Self-Test, and a $7.5 million BARDA contract for Marburg Virus Disease test development. The company guides Q1 2025 revenues between $27.5-31.5 million.

Positive

• Strong cash position of $267.8 million
• Core revenue growth of 10% year-over-year
• Sample Management Solutions revenue up 14%
• Diagnostics revenue increased 9%
• $7.5M BARDA contract awarded for Marburg virus test development

Negative

• 51% decline in total net revenues to $37.4M
• GAAP operating loss of $12.4M vs income of $3.9M in Q4 2023
• Gross margin declined to 36.2% from 46.3% year-over-year
• 98% decrease in COVID-19 revenues
• Expected Q1 2025 revenue guidance shows sequential decline

Insights

Financial Analyst

OraSure Technologies' Q4 2024 results reveal a company in strategic transition, with total revenue declining 51% to $37.4 million year-over-year due to the expected wind-down of COVID-19 testing. However, the 10% growth in core revenues to $36.5 million demonstrates the underlying strength of the company's fundamental business segments, with Diagnostics and Sample Management growing at 9% and 14% respectively.

The company's profitability metrics reflect this transition period, with gross margins contracting from 46.3% to 36.2% and a shift from operating income to a $12.4 million operating loss. This margin compression stems from both the loss of high-margin COVID revenue and an increasing proportion of international sales, which typically carry lower margins.

What's particularly notable is OraSure's cash position of $267.8 million, representing approximately 92% of the company's current market capitalization. This substantial cash reserve not only provides significant downside protection but also enables strategic investments during this transition phase. The December acquisition of Sherlock Biosciences for $5 million represents a pivotal strategic move, providing OraSure with an advanced molecular diagnostics platform that could substantially expand their addressable market.

The Sherlock acquisition signals a clear strategic pivot toward higher-value molecular diagnostics, with their first product targeting Chlamydia and Gonorrhea expected for FDA submission by end of 2025. This platform's potential for over-the-counter molecular testing represents a significant market opportunity, as it would bring lab-quality results directly to consumers without the need for specialized equipment or professional oversight.

Additional growth catalysts include the expanded FDA labeling for their HIV Self-Test to include adolescents 14 and older, potentially increasing market penetration in a critical demographic. The $7.5 million government contract (expandable to $11 million) for Marburg Virus testing development further diversifies their revenue streams while leveraging their core competencies in rapid diagnostics.

The Q1 2025 revenue guidance of $27.5-31.5 million suggests a sequential decline from Q4, though this may reflect typical seasonality patterns. The planned exit from Risk Assessment testing by mid-2025 represents another strategic streamlining to focus resources on higher-growth opportunities.

OraSure appears to be methodically repositioning itself from a COVID-beneficiary to a focused diagnostics innovator with multiple growth vectors. The market's current valuation, with the stock trading near cash value, suggests investors may be underappreciating both the stability of the core business and the potential of their strategic initiatives in molecular diagnostics.

BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024.

“Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by elevated uncertainty for some of our existing customers related to government funding sources,” said OraSure President and CEO Carrie Eglinton Manner. “We made tremendous progress in our strategic transformation in 2024, which gives us confidence that OTI is positioned to deliver growth in our core business and drive further productivity gains.”

She added, “Our strong balance sheet has allowed us to significantly advance our innovation strategy, including the acquisition of Sherlock Biosciences, which brings to our pipeline an advanced molecular platform that we expect will expand access to diagnostic insights through convenient, effortless tests. Overall, we continue to progress operationally to leverage our differentiated products and our strong customer relationships to drive profitable long-term growth and create shareholder value.”

Financial Highlights

	For the Three Months Ended December 31,									For the Years Ended December 31,
		2024			2023		% Change				2024			2023		% Change
Core Business (1)	$	36,482		$	33,310		10	%		$	138,950		$	143,219		(3)%
Molecular Services		13			907		(99	)			1,705			4,474		(62	)
COVID-19		950			41,664		(98	)			45,172			257,779		(82	)
Total Net Revenues	$	37,445		$	75,881		(51)%			$	185,827		$	405,472		(54)%

_{⁽¹⁾ Includes Diagnostics, Sample Management Solutions, Risk Assessment Testing, other products and services revenues, and non-product and services revenues.}

	For the Three Months Ended December 31,											For the Years Ended December 31,
		2024				2023			% Change				2024				2023			% Change
Net revenues	$	37,445			$	75,881			(51)%			$	185,827			$	405,472			(54)%
Gross profit		13,566				35,126			(61	)			79,390				171,652			(54	)
Gross margin		36.2	%			46.3	%						42.7	%			42.3	%
Non-GAAP gross profit		15,000				35,264			(57	)			82,490				173,262			(52	)
Non-GAAP gross margin		40.1	%			46.5	%						44.4	%			42.7	%
Operating income (loss)		(12,418	)			3,898			NM				(28,250	)			32,684			NM
Operating margin	(33.2)%					5.1	%					(15.2)%					8.1	%
Non-GAAP operating income (loss)		(6,745	)			11,151			NM				(6,422	)			62,350			NM
Non-GAAP operating margin	(18.0)%					14.7	%					(3.5)%					15.4	%
Net income (loss)		(10,794	)			20,073			NM				(19,500	)			53,655			NM
Non-GAAP net income (loss)		(4,230	)			13,521			NM				3,943				66,311			(94	)
Diluted GAAP EPS	$	(0.14	)		$	0.27			NM			$	(0.26	)		$	0.72			NM
Diluted Non-GAAP EPS	$	(0.06	)		$	0.18			NM			$	0.05			$	0.89			(94	)

_{NM – not meaningful}

• Total net revenues for the fourth quarter of 2024 decreased 51% to $37.4 million from $75.9 million in the fourth quarter of 2023 primarily due to the decline in COVID-19 revenues.
• Core revenues (all revenues excluding COVID-19 and Molecular Services revenues) of $36.5 million in the fourth quarter increased 10% year-over-year. Diagnostics revenues in the fourth quarter increased 9% year-over-year to $18.8 million and Sample Management Solutions revenues increased 14% to $14.8 million.
• COVID-19 revenues of $1.0 million in the fourth quarter decreased 98% year-over-year primarily due to the completion of our largest government contract earlier in 2024.
• GAAP gross margin was 36.2% in the fourth quarter of 2024 compared to 46.3% in the fourth quarter of 2023. Non-GAAP gross margin in the fourth quarter of 2024 was 40.1% compared to 46.5% in the fourth quarter of 2023¹. On a year-over-year basis, gross margin was impacted by the decline in COVID-19 revenues and the higher mix of international revenues.
• GAAP operating loss in the fourth quarter of 2024 was $12.4 million compared to operating income of $3.9 million in the fourth quarter of 2023. Non-GAAP operating loss was $6.7 million in the fourth quarter of 2024 compared to non-GAAP operating income of $11.2 million in the fourth quarter of 2023.
• Cash and cash equivalents were $267.8 million as of December 31, 2024. Cash flow from operations in the fourth quarter of 2024 was $0.1 million. During the fourth quarter, we deployed $5.0 million for the acquisition of Sherlock Biosciences.

_{¹ For additional information on non-GAAP financial measures and a reconciliation of the GAAP financial results to non-GAAP financial results, see the schedules below. A description of the adjustments made to the GAAP financial measures is included at the end of the schedules.}

Recent Business Developments

• OTI acquired Sherlock Biosciences in December to expand our innovation pipeline with the addition of a molecular diagnostics platform that, subject to approval by the U.S. Food and Drug Administration (FDA), is expected to provide rapid results with strong sensitivity and specificity in a disposable format that will be well-suited for over-the-counter usage. Sherlock’s first molecular self-test, for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), is in clinical trials and is expected to be submitted to the FDA by the end of 2025 for review.
• Received FDA approval for a labeling change to the OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range for the OraQuick® HIV Self-Test to include individuals 14 years of age and older. Previously the test was approved for use in those 17 and older.
• Received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve FDA 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus.
• Made significant progress in exiting our Risk Assessment testing business. We plan to continue to support our Risk Assessment customers and wind down remaining inventory during the first half of 2025.

Financial Guidance

The Company is guiding to Q1 2025 revenues of $27.5 million to $31.5 million. The Company anticipates Core revenues in Q1 2025 of $27 million to $31 million, which includes approximately $1 million of Risk Assessment testing revenues. The Company anticipates COVID-19 revenues in Q1 2025 of approximately $0.5 million.

Conference Call

The Company will host a conference call and audio webcast to discuss the Company’s fourth quarter 2024 results and certain business developments, beginning today at 5 p.m. Eastern Time. The call will include prepared remarks by management and a question and answer session.

A webcast of the conference call will be available on the investor relations page of OTI’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OTI’s website shortly after the call has ended and will be available for approximately 90 days. If a participant will be listen-only, they are encouraged to listen via the webcast.

For participants interested in asking a question during the conference call, please follow the link below to pre-register. After registering, you will be provided with your access details via email. It is recommended to dial in at least 15 minutes prior to the call start time.

https://register.vevent.com/register/BI400ff7eb0f2149dfa53af33625f6bdfb 

OTI intends to use the Investor Relations Section of its website as a means of disclosing material non-public information (MNPI) and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor OTI’s website in addition to following its press releases, SEC filings, public conference calls, presentations, and webcasts.

Financial Data (Unaudited)

	For the Three Months Ended December 31,							For the Years Ended December 31,
		2024				2023			2024				2023
Results of Operations
Net revenues	$	37,445			$	75,881		$	185,827			$	405,472
Cost of products and services sold		23,879				40,755			106,437				233,820
Gross profit		13,566				35,126			79,390				171,652
Operating expenses:
Research and development		6,087				6,991			26,047				33,728
Sales and marketing		6,992				6,906			30,986				36,319
General and administrative		12,905				14,005			46,215				58,191
Loss on impairments		—				3,326			4,392				10,829
Change in the estimated fair value of acquisition-related contingent consideration		—				—			—				(99	)
Total operating expenses		25,984				31,228			107,640				138,968
Operating income (loss)		(12,418	)			3,898			(28,250	)			32,684
Other income		2,911				16,822			12,249				23,574
Income (loss) before income taxes		(9,507	)			20,720			(16,001	)			56,258
Income tax expense		758				647			1,799				2,603
Loss on equity investment		(529	)			—			(1,700	)			—
Net income (loss)	$	(10,794	)		$	20,073		$	(19,500	)		$	53,655
Income (loss) per share:
Basic	$	(0.14	)		$	0.27		$	(0.26	)		$	0.73
Diluted	$	(0.14	)		$	0.27		$	(0.26	)		$	0.72
Weighted average shares outstanding:
Basic		74,597				73,499			74,434				73,348
Diluted		74,597				75,013			74,434				74,389

	For the Three Months Ended December 31,									For the Years Ended December 31,
		2024			2023		% Change				2024			2023		% Change
Consolidated Net Revenues
Diagnostics	$	18,768		$	17,219		9	%		$	75,917		$	73,694		3	%
Sample Management Solutions		14,809			13,044		14				51,046			54,274		(6	)
COVID-19 Diagnostics		950			41,617		(98	)			45,136			257,493		(82	)
Risk Assessment Testing		2,055			2,196		(6	)			8,354			9,736		(14	)
Other products and services		636			526		21				2,417			2,265		7
Molecular Services		13			907		(99	)			1,705			4,474		(62	)
COVID-19 Molecular Products		—			47		(100	)			36			286		(87	)
Net product and services revenues		37,231			75,556		(51	)			184,611			402,222		(54	)
Non-product and services revenues		214			325		(34	)			1,216			3,250		(63	)
Net revenues	$	37,445		$	75,881		(51)%			$	185,827		$	405,472		(54)%

Condensed Consolidated Balance Sheets (Unaudited)

	December 31, 2024			December 31, 2023
Assets
Cash and cash equivalents	$	267,763		$	290,407
Accounts receivable, net		23,816			40,171
Inventories		34,197			47,614
Other current assets		7,444			8,267
Property, plant and equipment, net		45,105			45,420
Intangible assets, net		17,134			1,206
Goodwill		41,831			35,696
Investment in equity method investee		28,300			—
Other noncurrent assets		15,269			14,064
Total assets	$	480,859		$	482,845
Liabilities and Stockholders’ Equity
Accounts payable	$	8,173		$	13,151
Deferred revenue		2,961			1,559
Other current liabilities		22,349			24,826
Other noncurrent liabilities		37,038			12,638
Stockholders’ equity		410,338			430,671
Total liabilities and stockholders’ equity	$	480,859		$	482,845

Additional Financial Data (Unaudited)

	For the Years Ended December 31,
		2024			2023
Capital expenditures	$	3,797		$	10,303
Proceeds from funding under government contract (1)		—			48,669
Depreciation and amortization		10,872			20,936
Stock-based compensation		11,920			10,729
Cash provided by operating activities	$	27,374		$	141,583

_{⁽¹⁾ Proceeds represent reimbursement for capital expenditures, engineering consulting costs, and guaranteed profit to cover project management costs.}

Consolidated Statement of Cash Flows (Unaudited)

	For the Years Ended December 31,
		2024				2023
OPERATING ACTIVITIES:
Net (loss) income	$	(19,500	)		$	53,655
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation		11,920				10,729
Depreciation and amortization		10,872				20,936
Loss on impairments		4,392				10,829
Other non-cash amortization		(564	)			3
Provision for credit losses		71				(462	)
Unrealized foreign currency gain		(263	)			103
Interest expense on finance leases		22				51
Loss on equity investment		1,700				—
Deferred income taxes		(657	)			102
Loss on sale of fixed assets		563				—
Change in the estimated fair value of acquisition-related contingent consideration		—				(99	)
Payment of acquisition-related contingent consideration		—				(19	)
Changes in assets and liabilities:
Accounts receivable		15,872				31,116
Inventories		13,096				48,228
Prepaid expenses and other assets		4,089				(2,499	)
Accounts payable		(7,577	)			(26,976	)
Deferred revenue		(219	)			(730	)
Accrued expenses and other liabilities		(6,443	)			(3,384	)
Net cash provided by operating activities		27,374				141,583
INVESTING ACTIVITIES:
Purchases of short-term investments		(53,244	)			(74,652	)
Investment in equity method investee		(30,000	)			—
Proceeds from maturities and redemptions of short-term investments		53,052				102,440
Purchases of property and equipment		(3,797	)			(5,802	)
Acquisition of business, net of cash acquired		(5,037	)			—
Purchase of property and equipment under government contracts		—				(4,501	)
Proceeds from funding under government contract (1)		—				48,669
Net cash (used in) provided by investing activities		(39,026	)			66,154
FINANCING ACTIVITIES:
Cash payments for lease liabilities		(842	)			(1,345	)
Proceeds from exercise of stock options		214				269
Payment of acquisition-related contingent consideration		—				(46	)
Repurchase of common stock		(3,548	)			(1,901	)
Net cash used in financing activities		(4,176	)			(3,023	)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		(6,816	)			1,713
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(22,644	)			206,427
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		290,407				83,980
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	267,763			$	290,407

About OraSure Technologies

OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

About Marburg Virus Disease (MVD) rapid antigen test

The Marburg Virus Disease (MVD) rapid antigen test project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005, and the Project Identifier is RRPV-24-06-DxR2-007 (OraSure).

Forward Looking Statements

This press release contains certain forward-looking statements, including with respect to products, product candidate development and manufacturing activities, regulatory submissions and authorizations, revenue growth and guidance, expected revenue from government orders, cost savings, cash flow, increasing margins and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to reduce our spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the demand for our COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; impact of replacing distributors; inventory levels at distributors and other customers; our ability to achieve its financial and strategic objectives and increase our revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of our products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to achieve and maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving our systems or those of our third-party contractors and IT service providers, suppliers and customers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures, the imposition of tariffs and banking stability. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

Statement Regarding Use of Non-GAAP Financial Measures

In this press release, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures, including non-GAAP gross margin, non-GAAP gross profit, non-GAAP net income (loss), non-GAAP operating income (loss), and non-GAAP earnings (loss) per share. Management believes that presentation of operating results using these non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods, while excluding certain expenses that may not be indicative of the Company’s recurring core business operating results. In addition, management believes these non-GAAP financial measures are useful to investors both because they (1) allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) are used by OraSure’s institutional investors and the analysis community to help them analyze the health of OraSure’s business. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.

OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's)

	For the Three Months Ended December 31,								For the Years Ended December 31,
		2024				2023				2024				2023
Revenue	$	37,445			$	75,881			$	185,827			$	405,472
GAAP Cost of products and services sold		23,879				40,755				106,437				233,820
GAAP Gross Margin		36.2	%			46.3	%			42.7	%			42.3	%
Stock compensation		195				138				734				564
Amortization of acquisition-related intangible assets		—				—				—				396
Reduction in workforce severance		239				—				1,366				369
Transformation related expenses		—				—				—				281
Inventory reserve for product line discontinuance		1,000				—				1,000				—
Non-GAAP Cost of Goods Sold		22,445				40,617				103,337				232,210
Non-GAAP Gross Margin		40.1	%			46.5	%			44.4	%			42.7	%
GAAP Operating Income (Loss)		(12,418	)			3,898				(28,250	)			32,684
Stock compensation		2,741				3,127				11,919				10,729
Amortization of acquisition-related intangible assets		103				150				279				1,549
Reduction in workforce severance		849				—				3,258				3,265
Inventory reserve for product line discontinuance		1,000				—				1,000				—
Loss on impairment		—				3,326				4,392				10,829
Transformation related expenses		—				—				—				707
Transaction costs		980				650				980				650
Government grant accounting		—				—				—				2,036
Change in fair value of acquisition-related contingent consideration		—				—				—				(99	)
Non-GAAP Operating Income (Loss)		(6,745	)			11,151				(6,422	)			62,350
GAAP Net Income (Loss)		(10,794	)			20,073			$	(19,500	)			53,655
Stock compensation		2,741				3,127				11,919				10,729
Amortization of acquisition-related intangible assets		103				150				279				1,549
Reduction in workforce severance		849				—				3,258				3,264
Inventory reserve for product line discontinuance		1,000				—				1,000				—
Loss on impairment		—				3,326				4,392				10,829
Transformation related expenses		—				—				—				707
Transaction costs		980				650				980				650
Change in fair value of acquisition-related contingent consideration		—				—				—				(99	)
Loss on equity investment		529				—				1,700				—
Additional profit from government contract		—				(12,802	)			—				(12,802	)
Tax effect of non-GAAP adjustments		362				(1,003	)			(85	)			(2,171	)
Non-GAAP Net Income (Loss)	$	(4,230	)		$	13,521			$	3,943			$	66,311
GAAP Earnings (Loss) Per Share:	$	(0.14	)		$	0.27			$	(0.26	)		$	0.72
Non-GAAP Earnings (Loss) Per Share:	$	(0.06	)		$	0.18			$	0.05			$	0.89
Diluted Shares Outstanding		74,597				75,013				74,434				74,389
Diluted Shares Outstanding Used For Computing Non-GAAP Earnings (Loss) Per Share		74,597				75,013				75,329				74,389

The following is a description of the adjustments made to GAAP financial measures:

• Stock Compensation: non-cash equity-based compensation provided to OraSure employees and directors
• Amortization of acquisition-related intangible assets: represents recurring amortization charges resulting from the acquisition of intangible assets associated with our business combinations
• Reduction in workforce severance: termination benefits associated with the Company’s workforce reduction associated with certain business events
• Inventory reserve for product line discontinuance: represents the write down of inventory associated with the risk assessment line of business that is discontinued
• Loss on impairment: charges related to the write down of Company’s intangibles, PP&E, or leased assets
• Transformation related expenses: transitory costs such as consulting and professional fees related to transformation initiatives
• Government contract accounting: As required under International Accounting Standard Board IAS 20, Accounting for Government Contracts and Disclosure of Government Assistance, our operating expenses associated with the Department of Defense expansion contract are reflected in operating expenses with offsetting reimbursement reflected in other income
• Change in fair value of acquisition-related contingent consideration: changes in the fair value of contingent consideration liability associated with estimate changes in reaching contingent consideration metrics
• Loss on equity investment: we have excluded our proportionate share of our equity method investee’s net loss as we do not have direct control over the investee’s operations or resulting revenue and expenses
• Tax impact associated with non-GAAP adjustments – tax expense/(benefit) due to non-GAAP adjustments

A reconciliation of our non-GAAP measures to their most directly comparable GAAP measures can also be found at: https://orasure.gcs-web.com/gaap-non-gaap-reconciliation

Investor Contact:	Media Contact:
Jason Plagman	Amy Koch
VP, Investor Relations	Director, Corporate Communications
investorinfo@orasure.com	media@orasure.com

FAQ

What caused OraSure's (OSUR) 51% revenue decline in Q4 2024?

The decline was primarily due to the completion of OraSure's largest government COVID-19 contract, with COVID-19 revenues dropping 98% to $1.0 million.

How much did OraSure's (OSUR) core business grow in Q4 2024?

Core revenues grew 10% year-over-year to $36.5 million, with Diagnostics up 9% to $18.8 million and Sample Management Solutions up 14% to $14.8 million.

What is OraSure's (OSUR) financial guidance for Q1 2025?

OraSure expects Q1 2025 revenues of $27.5-31.5 million, including core revenues of $27-31 million and COVID-19 revenues of approximately $0.5 million.

What strategic acquisitions did OraSure (OSUR) make in Q4 2024?

OraSure acquired Sherlock Biosciences for $5.0 million to expand their molecular diagnostics platform, with plans for an FDA submission for CT/NG self-test by end of 2025.